Anthem Biosciences IPO: The Bengaluru-based firm, Anthem Biosciences, has secured Rs 1,016 crore from anchor traders forward of its upcoming Preliminary Public Providing (IPO), which opens for public subscription on July 14.
Based on the BSE web site, the corporate has allotted 1.78 crore fairness shares to 60 anchor traders at Rs 570 per share, which is the higher finish of the IPO value band.
Anthem Biosciences anchor e-book record
The anchor e-book noticed participation from a number of outstanding world and home institutional traders. Right here is the record:
- Abu Dhabi Funding Authority
- Authorities Pension Fund World
- Eastspring Investments
- Amundi Funds
- PineBridge World Funds
- Société Générale
- HDFC MF
- ICICI Prudential MF
- Axis MF
- UTI MF
- Quant MF
- Motilal Oswal MF
Anthem Biosciences IPO: Value band, lot dimension, key particulars
This challenge is a suggestion on the market (OFS) by the corporate’s promoters, traders and different personnel materials. Which means the corporate won’t get any profit from this challenge and will probably be purely a wide range of recommendation. Nonetheless, data like lot dimension and value band has not been disclosed but.
Value band, lot dimension
The corporate has mounted the value band between Rs 540 and Rs 570 per share. Traders can apply for 26 shares in a single lot and multiples heaps.
Monetary efficiency
The corporate reported income of Rs 1,844 crore in FY25, a 30 per cent year-on-year enhance in comparison with Rs 1,419 crore in FY24. Whereas its revenue after tax (PAT) rose by 23 per cent to Rs 451 crore throughout the identical interval.
Listed opponents
The corporate has a number of listed business friends, a few of that are leaders within the sector, together with Sai Life Sciences Restricted, Syngene Worldwide, Suven Life Sciences and Divi’s Laboratories.
BRLMs, registrar particulars
JM Monetary, Citigroup World Markets India, JP Morgan India, and Nomura Monetary Advisory and Securities (India) are appearing because the book-running lead managers for the IPO. The corporate has appointed Kfin Applied sciences Restricted as registrar for the problems.
About Anthem Bioscience do?
Based in 2006, Anthem Biosciences is a Contract Analysis, Growth, and Manufacturing Organisation (CRDMO) centered on innovation and expertise. The corporate operates throughout all the pharmaceutical worth chain, together with drug discovery, growth, and manufacturing. It additionally produces and markets advanced fermentation-based Lively Pharmaceutical Elements (APIs) corresponding to probiotics, enzymes, peptides, dietary actives, vitamin analogues, and biosimilars.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be a part of our rising neighborhood at nextbusiness24.com
